Vaxeal has established strategic partnerships with leading European research institutions in healthcare, and clinical research centres (CEA, INSERM, HEGP/AP-HP, and CHUV) to expand its expertise in the fields of oncology and to reduce timelines for product development.
The formation of a strong intellectual portfolio is at the heart of Vaxeal’s strategy. Vaxeal continues to expand, to consolidate and to update its intellectual property position and product pipeline.
Vaxeal already signed exclusive worldwide license agreements for the protection of T-cell epitopes of the tumor antigens Survivin and Cyclin B1 with the Commissariat à l’EnergieAtomique (CEA).
